Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.46 |
| ▸ | NAMPT | P43490 | 7/20 | 0.45 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TTK | P33981 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19307230 | 1.00 | IMPDH2 (0.55) | IMPDH2ROCK2ROCK1MAPK1NAMPT | |
| SCHEMBL29614729 | 0.86 | IMPDH2 (0.54) | IMPDH2MAPK1PRMT3AURKB | |
| SCHEMBL19307170 | 0.86 | IMPDH2 (0.54) | IMPDH2MAPK1PRMT3AURKB | |
| SCHEMBL19307218 | 0.80 | RAB9A (0.47) | IMPDH2ROCK1HTT | |
| SCHEMBL29614745 | 0.80 | RAB9A (0.47) | IMPDH2ROCK1HTT | |
| SCHEMBL19307104 | 0.80 | IMPDH2 (0.42) | IMPDH2HTT | |
| SCHEMBL29614871 | 0.80 | IMPDH2 (0.42) | IMPDH2HTT | |
| SCHEMBL29614706 | 0.79 | KDM4E (0.53) | IMPDH2HTT | |
| SCHEMBL19307111 | 0.79 | KDM4E (0.53) | IMPDH2HTT | |
| SCHEMBL29450627 | 0.77 | IMPDH2 (0.71) | IMPDH2ROCK2ROCK1NAMPTPRMT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | CORNELL UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | PTGES, PTGS1, PTGES2 | IMPDH2 551/4885ROCK2 1134/4885ROCK1 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.